Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (10)

2023

  1. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2022

  1. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

    Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135

2018

  1. TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models

    Molecular Therapy, Vol. 26, Núm. 8, pp. 2047-2059

2014

  1. Apoptosis-related proteins are potential markers of neonatal hypoxic-ischemic encephalopathy (HIE) injury

    Neuroscience Letters, Vol. 558, pp. 143-148

2013

  1. Smad3 is required for the survival of proliferative intermediate progenitor cells in the dentate gyrus of adult mice

    Cell Communication and Signaling, Vol. 11, Núm. 1

2012

  1. EIF4F complex disruption causes protein synthesis inhibition during hypoxia in nerve growth factor (NGF)-differentiated PC12 cells

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 2, pp. 430-438

2011

  1. Dopamine and α-synuclein dysfunction in Smad3 null mice

    Molecular Neurodegeneration, Vol. 6, Núm. 1

2010

  1. New hierarchical phosphorylation pathway of the translational repressor eIF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress

    Journal of Biological Chemistry, Vol. 285, Núm. 45, pp. 34355-34363

2007

  1. Translation regulation after taxol treatment in NIH3T3 cells involves the elongation factor (eEF)2

    Experimental Cell Research, Vol. 313, Núm. 17, pp. 3694-3706

2006

  1. Hiperplasia facial y cerebral unilateral asociada a neurofibromatosis tipo 1. Presentación de cuatro pacientes

    Revista de Neurologia, Vol. 43, Núm. 6, pp. 346-352